FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992470724> ?p ?o ?g. }

• W1992470724 endingPage "38" @default.
• W1992470724 startingPage "35" @default.
• W1992470724 abstract "Allograft rejection in intestinal transplantation occurs frequently, and bacterial, fungal, and viral infections related to strong immunosuppression regimens remain an important complication posttransplantation. Induction therapy has enabled improvement in graft and patient survival rates.In analyze the effects of daclizumab and alemtuzumab as induction therapies on inflections complications and incidence of acute cellular rejection (ACR) during the early posttransplantation period.Between December 2000 and August 2009, we performed 43 intestinal transplantation procedures in 42 adult recipients (median [SD] age, 34.8 [9.5] years; male-female ratio, 22:20; isolated or multivisceral graft, 32/11), and compared findings during the first 30 days posttransplantation in 40 recipients. Patients were divided into 2 groups: 12 treated with daclizumab (Zenapax; Hoffman-La Roche Ltd, Basel, Switzerland): 8 isolated intestinal grafts and 4 multivisceral grafts) and 28 treated with alemtuzumab (Campath-1H: 22 isolated intestinal grafts and 6 multivisceral grafts). Maintenance immunosuppression was based on tacrolimus and steroids in the first group and low-dose tacrolimus in the second group.During the first month posttransplantation, 8 daclizumab recipients (66.6%) experienced 9 episodes of mild ACR, which were successfully treated with steroid therapy, and 8 patients (66.6%) developed a bacterial infection requiring treatment. Fourteen episodes of ACR occurred in 12 alemtuzumab recipients (42.8%): 11 mild, 1 mild to moderate, and 2 moderate; 16 patients (57.1%) required treatment for infections. Five-year patient cumulative survival was 66% in daclizumab recipients and 43% in alemtuzumab recipients. Five-year graft survivals was 66% in daclizumab recipients and 41% in alemtuzumab recipients. In both groups, P was not statistically significative.The infection rate is considerably high with both protocols. Alemtuzumab seems to offer better immunosuppression against ACRs during the first month posttransplantation." @default.
• W1992470724 created "2016-06-24" @default.
• W1992470724 creator A5000508933 @default.
• W1992470724 creator A5001100012 @default.
• W1992470724 creator A5001902894 @default.
• W1992470724 creator A5003452287 @default.
• W1992470724 creator A5012239760 @default.
• W1992470724 creator A5017943795 @default.
• W1992470724 creator A5020323314 @default.
• W1992470724 creator A5029645660 @default.
• W1992470724 creator A5032121417 @default.
• W1992470724 creator A5038891362 @default.
• W1992470724 creator A5039559137 @default.
• W1992470724 creator A5043937157 @default.
• W1992470724 creator A5053472275 @default.
• W1992470724 creator A5055722818 @default.
• W1992470724 creator A5057777607 @default.
• W1992470724 creator A5067281574 @default.
• W1992470724 creator A5070366828 @default.
• W1992470724 creator A5078408743 @default.
• W1992470724 creator A5084559422 @default.
• W1992470724 creator A5086034237 @default.
• W1992470724 creator A5088983987 @default.
• W1992470724 date "2010-01-01" @default.
• W1992470724 modified "2023-10-18" @default.
• W1992470724 title "Daclizumab and Alemtuzumab as Induction Agents in Adult Intestinal and Multivisceral Transplantation: Rejection and Infection Rates in 40 Recipients During the Early Postoperative Period" @default.
• W1992470724 cites W1976556158 @default.
• W1992470724 cites W1980626778 @default.
• W1992470724 cites W2032817278 @default.
• W1992470724 cites W2056297349 @default.
• W1992470724 cites W2093498786 @default.
• W1992470724 cites W2160634976 @default.
• W1992470724 doi "https://doi.org/10.1016/j.transproceed.2009.12.019" @default.
• W1992470724 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20172276" @default.
• W1992470724 hasPublicationYear "2010" @default.
• W1992470724 type Work @default.
• W1992470724 sameAs 1992470724 @default.
• W1992470724 citedByCount "12" @default.
• W1992470724 countsByYear W19924707242012 @default.
• W1992470724 countsByYear W19924707242014 @default.
• W1992470724 countsByYear W19924707242015 @default.
• W1992470724 countsByYear W19924707242016 @default.
• W1992470724 countsByYear W19924707242017 @default.
• W1992470724 countsByYear W19924707242021 @default.
• W1992470724 countsByYear W19924707242022 @default.
• W1992470724 crossrefType "journal-article" @default.
• W1992470724 hasAuthorship W1992470724A5000508933 @default.
• W1992470724 hasAuthorship W1992470724A5001100012 @default.
• W1992470724 hasAuthorship W1992470724A5001902894 @default.
• W1992470724 hasAuthorship W1992470724A5003452287 @default.
• W1992470724 hasAuthorship W1992470724A5012239760 @default.
• W1992470724 hasAuthorship W1992470724A5017943795 @default.
• W1992470724 hasAuthorship W1992470724A5020323314 @default.
• W1992470724 hasAuthorship W1992470724A5029645660 @default.
• W1992470724 hasAuthorship W1992470724A5032121417 @default.
• W1992470724 hasAuthorship W1992470724A5038891362 @default.
• W1992470724 hasAuthorship W1992470724A5039559137 @default.
• W1992470724 hasAuthorship W1992470724A5043937157 @default.
• W1992470724 hasAuthorship W1992470724A5053472275 @default.
• W1992470724 hasAuthorship W1992470724A5055722818 @default.
• W1992470724 hasAuthorship W1992470724A5057777607 @default.
• W1992470724 hasAuthorship W1992470724A5067281574 @default.
• W1992470724 hasAuthorship W1992470724A5070366828 @default.
• W1992470724 hasAuthorship W1992470724A5078408743 @default.
• W1992470724 hasAuthorship W1992470724A5084559422 @default.
• W1992470724 hasAuthorship W1992470724A5086034237 @default.
• W1992470724 hasAuthorship W1992470724A5088983987 @default.
• W1992470724 hasConcept C126322002 @default.
• W1992470724 hasConcept C141071460 @default.
• W1992470724 hasConcept C2779015954 @default.
• W1992470724 hasConcept C2779719350 @default.
• W1992470724 hasConcept C2780252810 @default.
• W1992470724 hasConcept C2909675724 @default.
• W1992470724 hasConcept C2911091166 @default.
• W1992470724 hasConcept C71924100 @default.
• W1992470724 hasConcept C90924648 @default.
• W1992470724 hasConceptScore W1992470724C126322002 @default.
• W1992470724 hasConceptScore W1992470724C141071460 @default.
• W1992470724 hasConceptScore W1992470724C2779015954 @default.
• W1992470724 hasConceptScore W1992470724C2779719350 @default.
• W1992470724 hasConceptScore W1992470724C2780252810 @default.
• W1992470724 hasConceptScore W1992470724C2909675724 @default.
• W1992470724 hasConceptScore W1992470724C2911091166 @default.
• W1992470724 hasConceptScore W1992470724C71924100 @default.
• W1992470724 hasConceptScore W1992470724C90924648 @default.
• W1992470724 hasIssue "1" @default.
• W1992470724 hasLocation W19924707241 @default.
• W1992470724 hasLocation W19924707242 @default.
• W1992470724 hasOpenAccess W1992470724 @default.
• W1992470724 hasPrimaryLocation W19924707241 @default.
• W1992470724 hasRelatedWork W1606991159 @default.
• W1992470724 hasRelatedWork W1965326757 @default.
• W1992470724 hasRelatedWork W2016596535 @default.
• W1992470724 hasRelatedWork W2033109203 @default.
• W1992470724 hasRelatedWork W2034020542 @default.
• W1992470724 hasRelatedWork W2060191360 @default.
• W1992470724 hasRelatedWork W2061913897 @default.
• W1992470724 hasRelatedWork W2065729608 @default.

• next